Core IM | Internal Medicine Podcast

Core IM Team

Core Internal Medicine via following series: 5 Pearls || Clinically relevant pearls Mind the Gap || Why do we do what we do? Gray Matters || Management Reasoning Hoofbeats || Dissecting clinical reasoning At the Bedside || Explore everyday challenges

  1. 4d ago

    #216 Clinician Grief: At the Beside Segment

    Have you ever lost a patient and found yourself thinking about them long after the shift ended? This episode explores the grief clinicians can carry after a patient dies, including the losses that aren’t always obvious. We also discuss ways to work through that grief, recognize when it becomes complicated, and lean on your team for support.   🔹Transcript and Shownotes 04:12 | What is Clinician Grief? 10:02 | Types of Losses 10:22 | Loss of a close relationship with a particular patient 12:56 | Loss due to a professional's identification with the pain of family members 13:56 | Loss of one's unmet goals and expectations and one's professional self-image and role 18:47 | Loss related to one's personal system of beliefs and assumptions about life 21:30 | Past unresolved losses or anticipated future losses 23:29 | The death of the self 25:44 | Coping Tags: CoreIM, Medical Education, Clinician Wellbeing, Burnout, Secondary Traumatic Stress, Complicated Grief, Coping With Grief, Medical humanities, medical ethics Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Our Sponsors: * Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

    #216 Clinician Grief: At the Beside Segment
  2. Jul 28

    #213 Hypertension First-Line Medications Troubleshooting | Bread & Butter Series

    Why can lower-dose combinations be more effective and better tolerated than maximizing one medication? How to troubleshoot common challenges such as amlodipine edema, gout, electrolyte abnormalities, and the patient who says they cannot tolerate anything? Why ACT (ARBs, Calcium Channel Blockers, Thiazides) is the preferred first-line framework, and how to personalize medication choices based on comorbidities and side effects. 🔹Sponsor: Oakstone CME Use the code "CORE25" for 25% off: https://www.coreimpodcast.com/MKSAP  🔹Transcript and Shownotes 03:00 | Diagnosing Hypertension  04:10 | When to Start Combination Therapy Instead of Monotherapy  07:00 | Choosing First-Line Therapy Using the ACT Framework  13:23 | Why ARBs Are Often Preferred Over ACE Inhibitors  16:02 | Choosing the Right ARB: Candesartan vs Losartan  18:39 | Comparing Potency & Duration Across First-Line Antihypertensives  20:54 | Amlodipine Edema: Why It Happens and How to Fix It  23:54 | Thiazides: Practical Tips, Electrolyte Problems & Class-Killer Side Effects  29:33 | Managing Patients Who 'Can't Tolerate' Blood Pressure Medications  Tags: Hypertension Management, High Blood Pressure, Primary Care, Internal Medicine, Core IM Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Our Sponsors: * Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

    #213 Hypertension First-Line Medications Troubleshooting | Bread & Butter Series
  3. Jul 15

    #212 Top 10 Highlights of the New Lipid Guidelines

    Learn from primary care docs what has been practiced and changed from the 2026 ACC/AHA Lipid Guidelines! Learn how the new CPR framework (Calculate, Personalize, Reclassify) and PREVENT risk calculator change statin decisions, why LDL targets are back, and when to use Lp(a), ApoB, and coronary artery calcium (CAC) testing. Discover updated risk-enhancing factors, expanded indications for non-statin therapies, and practical strategies to personalize lipid management for both primary and secondary 🔹Sponsor: Search “Amazon Pharmacy Nationwide Home Delivery" in your EHR to get home delivery (often same-day). Learn more here. 🔹Transcript and Shownotes:   01:17 | Highlight #1 & #2: CPR and PREVENT Score 03:14 | Highlight #3: Updated ASCVD Risk Categories Using the PREVENT Score 05:30 | Highlight #4: LDL Targets Are Back 07:20 | Highlight #5: High-Risk Conditions That Bypass the PREVENT Score 08:41 | Highlight #6: Lp(a) Screening for Everyone 11:51 | Highlight #7: When to Use ApoB Testing 13:16 | Highlight #8: Reproductive Risk Factors 15:29 | Highlight #9: Using CAC to Guide Statin Therapy 19:09 | Highlight #10: Non-Statin Therapies Tags: CoreIM, Internal Medicine, Medical Education, Cholesterol, Statins, LDL, ASCVD, Preventive Cardiology, LpA, ApoB, CAC, ACC2026, Cardiology, PrimaryCare  Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Our Sponsors: * Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

    #212 Top 10 Highlights of the New Lipid Guidelines
  4. Jun 29

    #211 Breaking Down MASLD vs. MASH and the MAESTRO-NASH & ESSENCE Trials: Beyond Journal Club Segment

    MASLD affects nearly one in three adults worldwide, yet many patients remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? When is a FIB-4 enough, and when should we move to elastography or hepatology referral? And are we finally entering an era where we can meaningfully treat MASH? In this Beyond Journal Club episode, we unpack the evolving language of steatotic liver disease and take a close look at two major trials: MAESTRO-NASH studying resmetirom, the first FDA-approved liver-directed therapy for MASH, and ESSENCE, evaluating semaglutide in biopsy-confirmed disease. Along the way, we explore what these biopsy-based histologic endpoints really mean, why placebo responses were surprisingly high, and whether improvements in steatohepatitis and fibrosis will ultimately translate into better clinical outcomes for patients. This episode is for clinicians trying to understand where the field is headed, which patients deserve closer attention, and how metabolic liver disease is increasingly becoming part of everyday primary care and hospital medicine. 🔹Sponsor: Oakstone CME Use the code "CORE25" for 25% off: https://www.coreimpodcast.com/MKSAP  🔹Transcript and Shownotes:   01:57 | Understanding MASLD as a Systemic Disease  05:45 | MASLD vs MASH vs Met-ALD: Spectrum Steatotic Liver Disease  08:55 | How to Screen for Fibrosis (FIB-4 & FibroScan)  16:15 | Lifestyle Treatment & Weight Loss Targets  19:00 | ESSENCE Trial: Semaglutide for MASH  21:58 | MAESTRO-NASH Trial: Resmetirom  27:27 | Future Treatments for MASH  30:51 | Key Takeaways for Clinicians  Tags: CoreIM, Internal Medicine, Medical Education, Hepatology, Fatty Liver Disease, Metabolic Dysfunction Associated Steatohepatitis, Nonalcoholic Fatty Liver Disease, Liver Fibrosis Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Our Sponsors: * Check out CovePure and use my code CovePure.com/coreim for a great deal: https://covepure.com * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io * Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy

    #211  Breaking Down MASLD vs. MASH and the MAESTRO-NASH & ESSENCE Trials: Beyond Journal Club Segment
4.8
out of 5
1,153 Ratings

About

Core Internal Medicine via following series: 5 Pearls || Clinically relevant pearls Mind the Gap || Why do we do what we do? Gray Matters || Management Reasoning Hoofbeats || Dissecting clinical reasoning At the Bedside || Explore everyday challenges

You Might Also Like